Herbal tools to help you beat asthma and lung infections
As we’ve learned all too well recently, we can’t take lung health for granted. Severe respiratory infections are on the rise, in addition to the chronic burdens of asthma, allergies, and air pollution., On top of that, many of us are experiencing smoke and particulate matter from the late summer wildfires burning, triggering asthmatic symptoms and compromising the respiratory health of everyone.
Unfortunately, the particulate matter from wildfire smoke and asthma can be factors that lower our resistance to respiratory tract infections as well. Fortunately, there are natural tools that not only intersect with the oxidative stress caused by smoke inhalation and the inflammation that contributes to asthma, but also help protect us from respiratory infections.
Lung inflammation is a common problem
Asthma, a long-term condition that affects people of all ages, causes wheezing, breathlessness, chest tightness, and coughing. Along with chronic obstructive pulmonary disease (COPD), asthma is a condition associated with inflammation in the lung airways.,,,
The inflammation that occurs with asthma is known as a “Th2 shift.” This means that the immune system shifts away from an infection-fighting (Th1) state and towards an inflammatory (Th2) state.,
One of the culprits in triggering a Th2 shift and thus increasing inflammation is a protein known as HMGB1. HMGB1 levels were found to be five times higher in the lungs of patients with asthma than in healthy subjects, and levels were also correlated with asthma severity.,, HMGB1 is a hot target for novel therapies for asthma, and also for severe respiratory infections, as we’ll discuss shortly.
The lung inflammation associated with asthma not only makes it difficult to breathe, but makes it harder for the immune system to fight off invaders.
The lung inflammation associated with asthma not only makes it difficult to breathe, but makes it harder for the immune system to fight off invaders., As a result, asthma increases the risk of respiratory infections.,,, Respiratory infections in turn exacerbate the symptoms of asthma,,,, creating a vicious circle. When one has these heightened risks, it is important to take extra protective steps.
Well-modulated inflammatory processes actually help clear lung infections. In severe infections, however, the inflammatory response can spin out of control when the body releases too many inflammatory cytokines (peptides) into the blood too quickly.,, The rapid and intense nature of the excessive release of cytokines can give rise to serious, possibly fatal lung damage. One of the molecules responsible for this flood of cytokines is our previously-mentioned villain, HMGB1.
While the scientific community actively works to identify anti-inflammatory and antiviral drugs to treat lung diseases, it’s worth examining the botanicals that have been used for centuries in traditional medicine to alleviate some of these problems.
In a previous article we discussed Andrographis paniculata and several other natural products with infection-fighting properties. Today we’ll focus on traditional herbal medicines for asthma, and see how they may also help fight viral infections.
How herbs help asthma and viral infections
Scientists at the Icahn School of Medicine at Mount Sinai in New York have extensively studied the use of herbs for asthma. They developed a blend of three Chinese herbal medicines known as ASHMI, which stands for Anti-Asthma Simplified Herbal Medicine Intervention. The ASHMI formula is comprised of the three most effective herbs identified in a traditional 14-herb formula (MSSM-02) with a long history of use in China. These include a water extract of Gan-Cao (Glycyrrhiza uralensis), commonly known as Chinese licorice; Ling-Zhi (Ganoderma lucidum), a medicinal mushroom commonly known as reishi; and Ku-Shen (Sophora flavescens), also known as shrubby sophora.
ASHMI has been studied extensively in the laboratory and in mice,,,,,, and also has been evaluated in human clinical trials., Remarkably, in a placebo-controlled trial conducted over a four-week period, ASHMI was as effective as the standard corticosteroid treatment in controlling moderate to severe asthma symptoms, yet lacked the adverse effect of adrenal suppression.
There was synergy among the three herbs, such that the ASHMI blend was more effective than any single constituent.
In studies of mice with established asthmatic responses, ASHMI was shown to provide persistent protection against lung inflammation without suppressing the immune system as a whole. Immunosuppression, of course, is an adverse effect associated with corticosteroid use. In the mice and the human study, the Th2-mediated allergic response was reduced, and there was a significant increase in the level of interferon, a cytokine that is essential for antiviral defenses. Notably, there was synergy among the three herbs, such that the ASHMI blend was more effective than any single constituent.
Numerous studies suggest that the herbs that comprise ASHMI may help ameliorate not only asthma, but also viral respiratory infections.
Glycyrrhizin, the predominant bioactive substance in , has been shown to decrease the production of inflammatory cytokines,, improve the Th1/Th2 balance, and ameliorate lung injury in animal models of inflammation. Licorice also contains phytonutrients known as flavonoids that have been shown to help control lung inflammation., In the context of viral respiratory infections, glycyrrhizin has been shown to tamp down inflammatory cytokines, enhance interferon production, and inhibit viral replication.,,
Glycyrrhizin significantly increased survival in mice exposed to a lethal quantity of influenza virus.
Potential remedies for viral infections can act either on the viral machinery itself or on host cells, and glycyrrhizin may well do both. It has been shown to bind to a cellular receptor known as ACE2 by which certain viruses enter the cell, thereby blocking the virus from accessing the cell’s machinery for further replication., This same cellular receptor also plays an important role in lung injury induced by influenza viruses.,, In mice exposed to a lethal quantity of influenza virus, glycyrrhizin was shown to increase survival when administered before and during the infection.
Glycyrrhizin also has the potential to block lung damage by binding and inhibiting HMGB1,, which, as mentioned, has been implicated in the flood of cytokines that is associated with severe viral infections.,,, Scientists at the Karolinska Institute in Sweden note an urgent need for human trials for glycyrrhizin and other potential HMGB1 blockers: “The collated science shows that HMGB1 probably plays a pivotal part in the development of acute lung damage, regardless of cause…In publishing our review paper, we hope to give guidance on existing drugs with the potential to mitigate HMGB1-mediated damage,” says Professor Andersson, the head of the laboratory, who has been researching this protein for approximately 20 years.
Note: It’s always a good idea to consult a qualified health professional if you are considering an herbal supplement regimen including Glycyrrhiza, as it can interact with prescribed medications and affect blood pressure in some individuals.
The second component of ASHMI, the medicinal mushroom known as reishi, has been shown to reduce cellular secretion of inflammatory cytokines,, and to restore a healthy Th1/Th2 balance in patients with allergies. In cells collected from asthma patients, a reishi extract suppressed the inflammation mediated by a cytokine known as tumor necrosis factor (TNF-α). TNF-α is an important player not only in asthma, but also mediates the inflammatory response that can exacerbate symptoms of infections, making reishi potentially useful in both contexts. Reishi has been shown in animal studies to reduce inflammation in both the gut and the lungs.,,
Reishi was shown to inhibit an influenza virus enzyme known as neuraminidase, which is essential for viral replication.
The medicinal mushroom reishi also contains water-soluble substances (triterpenoids) with direct anti-viral effects. Reishi was shown to inhibit an influenza virus enzyme known as neuraminidase (NA), which is essential for viral replication. NA inhibitors are the main drugs used to treat influenza.
Reishi additionally contains β-glucans, which are polysaccharides (small carbohydrates) with prebiotic properties. When β-glucans are ingested, they help support the growth of healthy bacteria in the gut, reduce inflammation, and boost immunity.,, A healthy microbiota helps reduce the risk of infections, while a microbiota that is out of balance can make it easier for viruses, bacteria, and fungal infections to take hold.
The third component of ASHMI, shrubby sophora (Sophora flavescens), also has been shown to modulate the production of inflammatory cytokines, and reduce smooth muscle contraction in samples taken from asthmatic mice. The contraction of smooth muscles contributes to the narrowing of the airways that is the hallmark of asthma attacks. A bioactive substance found in S. flavescens, known as matrine, has been shown to reduce cigarette smoke-induced lung inflammation in mice, suggesting that matrine may also help ameliorate COPD.
S. flavescens contains antiviral substances as well.,, An extract of S. flavescens was shown to inhibit influenza virus NA activity by 90%, an effect that was attributed to a bioactive ingredient known as a pterocarpan. “We believe that this lead structure may be highly beneficial for the development of new drugs to combat this serious disease,” conclude the study authors.
S. flavescens also contains flavonoids that may curtail the lung damage associated with respiratory infections.
S. flavescens also contains flavonoids that may curtail the lung damage associated with respiratory infections, based on evidence from studies of tuberculosis in mice. One particular flavonoid is capable of blocking a viral-induced cellular pathway known by its acronym, RANTES. The RANTES pathway is implicated not only in asthma attacks, but also in lung inflammation after viral infection. This suggests that the components of sophora may be beneficial for both indications.
The herbs presented here have the potential to support lung health and, in particular, to ameliorate the effects of asthma and respiratory infections. While they have been tested in the clinic for asthma, the case for their use for respiratory infections is based on preclinical studies and traditional use. The evidence from these studies is compelling, however, and justifies clinical trials of these natural products as tools for respiratory health and protection.
Click here to see References
 Robinson CL, et al. Effect of urbanisation on asthma, allergy and airways inflammation in a developing country setting. Thorax. 2011 Dec;66(12):1051-7.
 Juhn YJ. Risks for infection in patients with asthma (or other atopic conditions): is asthma more than a chronic airway disease? J Allergy Clin Immunol. 2014 Aug;134(2):247-57.
 Malaviya R, et al. Anti-TNFα therapy in inflammatory lung diseases. Pharmacol Ther. 2017 Dec;180:90-8.
 Maillet I, et al. Allergic lung inflammation is mediated by soluble tumor necrosis factor (TNF) and attenuated by dominant-negative TNF biologics. Am J Respir Cell Mol Biol. 2011 Oct;45(4):731-9.
 Caminati M, et al. Type 2 immunity in asthma. World Allergy Organ J. 2018 Jun 26;11(1):13.
 Mazzarella G, et al. Th1/Th2 lymphocyte polarization in asthma. Allergy. 2000;55 Suppl 61:6-9.
 Vieira Braga FA, et al. A cellular census of human lungs identifies novel cell states in health and in asthma. Nat Med. 2019 Jul;25(7):1153-63.
 Berger A. Th1 and Th2 responses: what are they? BMJ. 2000 Aug 12;321(7258):424.
 Ma L, et al. High mobility group box 1: a novel mediator of Th2-type response-induced airway inflammation of acute allergic asthma. J Thorac Dis. 2015 Oct;7(10):1732-41.
 Hou C, et al. High mobility group protein B1 (HMGB1) in asthma: comparison of patients with chronic obstructive pulmonary disease and healthy controls. Mol Med. 2011;17(7-8):807-15.
 Watanabe T, et al. Increased levels of HMGB-1 and endogenous secretory RAGE in induced sputum from asthmatic patients. Respir Med. 2011 Apr;105(4):519-25.
 Di Candia L, et al. HMGB1 is upregulated in the airways in asthma and potentiates airway smooth muscle contraction via TLR4. J Allergy Clin Immunol. 2017 Aug;140(2):584-7.
 Koch S, Finotto S. Role of interferon-λ in allergic asthma. J Innate Immun. 2015;7(3):224-30.
 Edwards MR, et al. Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness. J Allergy Clin Immunol. 2017 Oct;140(4):909-20.
 Green RM, et al. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ. 2002 Mar 30;324(7340):763.
 Moran TM, et al. Interleukin-4 causes delayed virus clearance in influenza virus-infected mice. J Virol. 1996 Aug;70(8):5230-5.
 Ekbom E, et al. Asthma and treatment with inhaled corticosteroids: associations with hospitalisations with pneumonia. BMC Pulm Med. 2019 Dec 19;19(1):254.
 Hossain FMA, et al. The interplay between host immunity and respiratory viral infection in asthma exacerbation. Immune Netw. 2019 Sep 9;19(5):e31.
 Kloepfer KM, Gern JE. Virus/allergen interactions and exacerbations of asthma. Immunol Allergy Clin North Am. 2010 Nov;30(4):553-63.
 Yoo JK, et al. Viral infection of the lung: host response and sequelae. J Allergy Clin Immunol. 2013 Dec;132(6):1263-76.
 Tisoncik JR, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32.
 Liu Q, et al. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016 Jan;13(1):3-10.
 Mahallawi WH, et al. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018 Apr;104:8-13.
 Peiris JS, et al. Host response to influenza virus: protection versus immunopathology. Curr Opin Immunol. 2010 Aug;22(4):475-81.
 Andersson U, et al. Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19? Mol Med. 2020 May 7;26(1):42.
 Wen MC, et al. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. J Allergy Clin Immunol. 2005 Sep;116(3):517-24.
 Li XM, et al. The Chinese herbal medicine formula MSSM-002 suppresses allergic airway hyperreactivity and modulates TH1/TH2 responses in a murine model of allergic asthma. J Allergy Clin Immunol. 2000 Oct;106(4):660-8.
 Busse PJ, et al. The traditional Chinese herbal formula ASHMI inhibits allergic lung inflammation in antigen-sensitized and antigen-challenged aged mice. Ann Allergy Asthma Immunol. 2010 Mar;104(3):236-46.
 Srivastava K, et al. Anti-Asthma Simplified Herbal Medicine Intervention-induced long-lasting tolerance to allergen exposure in an asthma model is interferon-γ, but not transforming growth factor-β dependent. Clin Exp Allergy. 2010 Nov;40(11):1678-88.
 Srivastava KD, et al. The anti-asthma Chinese herbal formula ASHMI provides more persistent benefits than dexamethasone in a murine asthma model. J Allergy Clin Immunol. 2011 Feb 1;127(2):AB261.
 Srivastava K, et al. The anti-asthma herbal medicine ASHMI acutely inhibits airway smooth muscle contraction via prostaglandin E2 activation of EP2/EP4 receptors. Am J Physiol Lung Cell Mol Physiol. 2013 Dec;305(12):L1002-10.
 Zhang T, et al. Pharmacology and immunological actions of a herbal medicine ASHMI on allergic asthma. Phytother Res. 2010 Jul;24(7):1047-55.
 Jayaprakasam B, et al. Constituents of the anti-asthma herbal formula ASHMI(TM) synergistically inhibit IL-4 and IL-5 secretion by murine Th2 memory cells, and eotaxin by human lung fibroblasts in vitro. J Integr Med. 2013 May;11(3):195-205.
 Kelly-Pieper K, et al. Safety and tolerability of an antiasthma herbal formula (ASHMI) in adult subjects with asthma: a randomized, double-blinded, placebo-controlled, dose-escalation phase I study. J Altern Complement Med. 2009 Jul;15(7):735-43.
 Matsui S, et al. Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line. Int Immunopharmacol. 2004 Dec 15;4(13):1633-44.
 Ram A, et al. Glycyrrhizin alleviates experimental allergic asthma in mice. Int Immunopharmacol. 2006 Sep;6(9):1468-77.
 Fouladi S, et al. The in vitro impact of glycyrrhizic acid on CD4+ T lymphocytes through OX40 receptor in the patients with allergic rhinitis. Inflammation. 2018 Oct;41(5):1690-1701.
 Qu L, et al. Glycyrrhizic acid ameliorates LPS-induced acute lung injury by regulating autophagy through the PI3K/AKT/mTOR pathway. Am J Transl Res. 2019 Apr 15;11(4):2042-55.
 Yang N, et al. Glycyrrhiza uralensis flavonoids present in anti-asthma formula, ASHMI™, inhibit memory Th2 responses in vitro and in vivo. Phytother Res. 2013 Sep;27(9):1381-91.
 Michaelis M, et al. Glycyrrhizin inhibits highly pathogenic H5N1 influenza A virus-induced pro-inflammatory cytokine and chemokine expression in human macrophages. Med Microbiol Immunol. 2010 Nov;199(4):291-7.
 Michaelis M, et al. Glycyrrhizin exerts antioxidative effects in H5N1 influenza A virus-infected cells and inhibits virus replication and pro-inflammatory gene expression. PLoS One. 2011;6(5):e19705.
 Feng Yeh C, et al. Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. J Ethnopharmacol. 2013 Jul 9;148(2):466-73.
 Cinatl T, et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003 Jun 14;361(9374):2045-6.
 Luo P, et al. Pharmacological perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19. Int J Antimicrob Agents. 2020 Apr 24:105995.
 Yang P, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. 2014 Nov 13;4:7027.
 Gu H, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep. 2016 Jan 27;6:19840.
 Chen L, Hao G. The role of angiotensin-converting enzyme 2 in coronaviruses/influenza viruses and cardiovascular disease. Cardiovasc Res. 2020 Apr 8:cvaa093.
 Utsunomiya T, et al. Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality of mice infected with lethal doses of influenza virus. Antimicrob Agents Chemother. 1997 Mar;41(3):551-6.
 Mollica L, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol. 2007 Apr;14(4):431-41.
 Moisy D, et al. HMGB1 protein binds to influenza virus nucleoprotein and promotes viral replication. J Virol. 2012 Sep;86(17):9122-33.
 Patel MC, et al. Serum high-mobility-group box 1 as a biomarker and a therapeutic target during respiratory virus infections. mBio. 2018 Mar 13;9(2):e00246-18.
 Wang H, et al. Potential role of high mobility group box 1 in viral infectious diseases. Viral Immunol. 2006 Spring;19(1):3-9.
 Manti S, et al. Induction of high-mobility group Box-1 in vitro and in vivo by respiratory syncytial virus. Pediatr Res. 2018 May;83(5):1049-56.
 Ives J, et al. HMGB1 protein may play a key role in pulmonary inflammation, tissue damage in severe COVID-19 cases [Internet]. Sydney (Australia): News-Medical Life Sciences; 2020 [cited 2020 May 12.] Available from: https://www.news-medical.net/news/20200508/HMGB1-protein-may-play-a-key-role-in-pulmonary-inflammation-tissue-damage-in-severe-COVID-19-cases.aspx
 Deutch MR, et al. Bioactive candy: effects of licorice on the cardiovascular system. Foods. 2019 Oct 14;8(10):495.
 Dudhgaonkar S, et al. Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum. Int Immunopharmacol. 2009 Oct;9(11):1272-80.
 Liang CJ, et al. Ganoderma lucidum polysaccharides reduce lipopolysaccharide-induced interleukin-1 β expression in cultured smooth muscle cells and in thoracic aortas in mice. Evid Based Complement Alternat Med. 2014;2014:305149.
 Bhardwaj N, et al. Suppression of inflammatory and allergic responses by pharmacologically potent fungus Ganoderma lucidum. Recent Pat Inflamm Allergy Drug Discov. 2014;8(2):104-17.
 Liu C, et al. Ganoderic acid C1 isolated from the anti-asthma formula, ASHMI™ suppresses TNF-α production by mouse macrophages and peripheral blood mononuclear cells from asthma patients. Int Immunopharmacol. 2015 Aug;27(2):224-31.
 Rutigliano JA, Graham BS. Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection. J Immunol. 2004 Sep 1;173(5):3408-17.
 Wei B, et al. Suppression of Th17 cell response in the alleviation of dextran sulfate sodium-induced colitis by Ganoderma lucidum polysaccharides. J Immunol Res. 2018 May 20;2018:2906494.
 Chen J, et al. Protective roles of polysaccharides from Ganoderma lucidum on bleomycin-induced pulmonary fibrosis in rats. Int J Biol Macromol. 2016 Nov;92:278-81.
 Xie J, et al. Ganoderma lucidum polysaccharide improves rat DSS-induced colitis by altering cecal microbiota and gene expression of colonic epithelial cells. Food Nutr Res. 2019 Feb 12;63.
 Zhang W, et al. Antiviral effects of two Ganoderma lucidum triterpenoids against enterovirus 71 infection. Biochem Biophys Res Commun. 2014 Jul 4;449(3):307-12.
 Zhu Q, et al. Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design. Sci Rep. 2015 Aug 26;5:13194.
 Jin M, et al. Effects of polysaccharide from mycelia of Ganoderma lucidum on intestinal barrier functions of rats. Int J Biol Macromol. 2017 Jan;94(Pt A):1-9.
 Jayachandran M, et al. A critical review on health promoting benefits of edible mushrooms through gut microbiota. Int J Mol Sci. 2017 Sep 8;18(9):1934.
 Li K, et al. Effects of Ganoderma lucidum polysaccharides on chronic pancreatitis and intestinal microbiota in mice. Int J Biol Macromol. 2016 Dec;93(Pt A):904-12
 Ichinohe T, et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5354-9.
 Li N, et al. The commensal microbiota and viral infection: a comprehensive review. Front Immunol. 2019 Jul 4;10:1551.
 Cho BO, et al. In vitro anti-inflammatory and anti-oxidative stress activities of Kushenol C isolated from the roots of Sophora flavescens. Molecules. 2020 Apr 12;25(8):1768.
 Yang N, et al. The Sophora flavescens flavonoid compound trifolirhizin inhibits acetylcholine induced airway smooth muscle contraction. Phytochemistry. 2013 Nov;95:259-67.
 Yu X, et al. Matrine reduces cigarette smoke-induced airway neutrophilic inflammation by enhancing neutrophil apoptosis. Clin Sci (Lond). 2019 Feb 18;133(4):551-64.
 Sohn HY, et al. Antimicrobial and cytotoxic activity of 18 prenylated flavonoids isolated from medicinal plants: Morus alba L., Morus mongolica Schneider, Broussnetia papyrifera (L.) Vent, Sophora flavescens Ait and Echinosophora koreensis Nakai. Phytomedicine. 2004 Nov;11(7-8):666-72.
 Ren G , et al. Antiviral activity of sophoridine against enterovirus 71 in vitro. J Ethnopharmacol. 2019 May 23;236:124-8.
 Kwon HJ, et al. In vitro anti-reovirus activity of kuraridin isolated from Sophora flavescens against viral replication and hemagglutination. J Pharmacol Sci. 2015 Aug;128(4):159-69.
 Ryu YB, et al. Pterocarpans and flavanones from Sophora flavescens displaying potent neuraminidase inhibition. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6046-9.
 Liu D , et al. Sophora flavescens protects against mycobacterial trehalose dimycolate-induced lung granuloma by inhibiting inflammation and infiltration of macrophages. Sci Rep. 2018 Mar 2;8(1):3903.
 Chiou WF, et al. 8-Prenylkaempferol suppresses influenza a virus-induced RANTES production in A549 cells via blocking PI3K-mediated transcriptional activation of NF-κB and IRF3. Evid Based Complement Alternat Med. 2011;2011:920828.
 Chihara J, et al. Elevation of the plasma level of RANTES during asthma attacks. J Allergy Clin Immunol. 1997 Dec;100(6 Pt 2):S52-5.
 Matsukura S, et al. Expression of RANTES by normal airway epithelial cells after influenza virus A infection. Am J Respir Cell Mol Biol. 1998 Feb;18(2):255-64.